Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Ranging Study of Ensifentrine in Moderate to Severe COPD
NCT03443414Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Jun 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Verona Pharma. Primary endpoint: Mean Change From Baseline in Peak Forced Expiratory Volume in One Second at 4 weeks. Started Jun 2017; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03443414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443414.